These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16299536)

  • 21. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.
    Carette JE; Graat HC; Schagen FH; Abou El Hassan MA; Gerritsen WR; van Beusechem VW
    J Gene Med; 2005 Aug; 7(8):1053-62. PubMed ID: 15756711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
    Dorer DE; Nettelbeck DM
    Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.
    Pei DS; Zheng JN
    Expert Opin Biol Ther; 2010 Jun; 10(6):917-26. PubMed ID: 20402550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic virotherapy for cancer treatment: challenges and solutions.
    Davis JJ; Fang B
    J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic viral therapies - the clinical experience.
    Aghi M; Martuza RL
    Oncogene; 2005 Nov; 24(52):7802-16. PubMed ID: 16299539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
    Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
    Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential impact of hypoxia on the success of oncolytic virotherapy.
    Hay JG
    Curr Opin Mol Ther; 2005 Aug; 7(4):353-8. PubMed ID: 16121701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic adenoviruses as antiglioma agents.
    Jiang H; McCormick F; Lang FF; Gomez-Manzano C; Fueyo J
    Expert Rev Anticancer Ther; 2006 May; 6(5):697-708. PubMed ID: 16759161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naturally oncolytic viruses.
    Roberts MS; Lorence RM; Groene WS; Bamat MK
    Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
    Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic viruses as therapeutic agents.
    Wildner O
    Ann Med; 2001 Jul; 33(5):291-304. PubMed ID: 11491186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
    Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
    Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
    Hoffmann D; Meyer B; Wildner O
    J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.